Johnson & Johnson (JNJ)vsSomalogic Inc (SLGC)
JNJ
Johnson & Johnson
$224.20
+0.60%
HEALTHCARE · Cap: $546.90B
SLGC
Somalogic Inc
$9.89
0.00%
HEALTHCARE · Cap: $396.23M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 117812% more annual revenue ($96.36B vs $81.72M). JNJ leads profitability with a 21.8% profit margin vs -159.5%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
SLGC
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-39.8%
Fair Value
$160.43
Current Price
$224.20
$63.77 premium
Margin of Safety
-12.9%
Fair Value
$1.86
Current Price
$9.89
$8.03 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
No standout strengths identified
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -23.7% — below average capital efficiency
Revenue declined 47.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : SLGC
SLGC has a balanced fundamental profile.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : SLGC
The primary concerns for SLGC are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while SLGC is a turnaround play — different risk/reward profiles.
SLGC carries more volatility with a beta of 1.64 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 29/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Somalogic Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
SomaLogic Inc. (SLGC) is a pioneering biotechnology company specializing in protein biomarker discovery and analysis, harnessing its proprietary SomaScan® platform to provide insights that advance precision medicine. By utilizing an extensive protein library, the company aims to develop sophisticated diagnostics and therapeutic applications across various health conditions, including cancer, cardiovascular diseases, and metabolic disorders. SomaLogic is positioned at the forefront of the biomarker industry, driving innovation in research and clinical settings while forming strategic partnerships to expand its reach and enhance the adoption of its technologies. With a strong focus on data-driven health solutions, SomaLogic is committed to improving patient outcomes and enabling personalized therapeutic strategies.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?